MaxCyte MXCT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from MaxCyte’s reported figures.
Based on trailing twelve months.
The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about MaxCyte's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MaxCyte's return on equity?
- MaxCyte (MXCT) reported return on equity of -21.3% in Q1 2026.
- How has MaxCyte's return on equity changed year-over-year?
- MaxCyte's return on equity decreased by 8.5% year-over-year, from -19.6% to -21.3%.
- What is the long-term trend for MaxCyte's return on equity?
- Over 5 years (2020 to 2025), MaxCyte's return on equity has grown at a -14.1% compound annual growth rate (CAGR), from -50.5% to -23.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.